Ellumigen Breakthrough™
Ellumigen Breakthrough™
Ellumigen Breakthrough™
Ellumigen Breakthrough™
From Raw Data to Insights in Minutes.
From Raw Data to Insights in Minutes.
From Raw Data to Insights in Minutes.
Not Months.
Not Months.
Not Months.
The end-to-end AI-powered translational-multiomics platform that transforms raw sequencing and curated study data into actionable insights.
Preclinical, Clinical, and RWE.
The end-to-end AI-powered translational-multiomics platform that transforms raw sequencing and curated study data into actionable insights.
Preclinical, Clinical, and RWE.
The end-to-end AI-powered translational-multiomics platform that transforms raw sequencing and curated study data into actionable insights.
Preclinical, Clinical, and RWE.
The end-to-end AI-powered translational-multiomics platform that transforms raw sequencing and curated study data into actionable insights.
Preclinical, Clinical, and RWE.
Interact with your data using our natural language chat, our rich bioinformatics platform, or your own AI models and tools—all powered by a high-performance structured database.
Interact with your data using our natural language chat, our rich bioinformatics platform, or your own AI models and tools—all powered by a high-performance structured database.
Interact with your data using our natural language chat, our rich bioinformatics platform, or your own AI models and tools—all powered by a high-performance structured database.
Interact with your data using our natural language chat, our rich bioinformatics platform, or your own AI models and tools—all powered by a high-performance structured database.
Feature
Feature
Feature
Feature
Benefit
Benefit
Benefit
Converts your study data and raw sequencing into a structured, high-performance database
Converts your study data and raw sequencing into a structured, high-performance database
Converts your study data and raw sequencing into a structured, high-performance database
Converts your study data and raw sequencing into a structured, high-performance database
One workspace for true end-to-end translational-multiomics insight across all your studies
One workspace for true end-to-end translational-multiomics insight across all your studies
One workspace for true end-to-end translational-multiomics insight across all your studies
One workspace for true end-to-end translational-multiomics insight across all your studies
Conversational analytics – explore your data through natural-language chat
Conversational analytics – explore your data through natural-language chat
Conversational analytics – explore your data through natural-language chat
Conversational analytics – explore your data through natural-language chat
Instant hypothesis generation and testing – zero code, zero wait
Instant hypothesis generation and testing – zero code, zero wait
Instant hypothesis generation and testing – zero code, zero wait
Instant hypothesis generation and testing – zero code, zero wait
Describe-to-build visuals – simply state the plot or table you need
Describe-to-build visuals – simply state the plot or table you need
Describe-to-build visuals – simply state the plot or table you need
Describe-to-build visuals – simply state the plot or table you need
Publication-ready figures in seconds
Publication-ready figures in seconds
Publication-ready figures in seconds
Publication-ready figures in seconds
Access to the latest chat models
Access to the latest chat models
Access to the latest chat models
Access to the latest chat models
Latest LLM power applied directly to your data
Latest LLM power applied directly to your data
Latest LLM power applied directly to your data
Latest LLM power applied directly to your data
Export any chat to Python notebooks
Export any chat to Python notebooks
Export any chat to Python notebooks
Export any chat to Python notebooks
Transparent, reproducible, extensible workflows
Transparent, reproducible, extensible workflows
Transparent, reproducible, extensible workflows
Transparent, reproducible, extensible workflows
Direct Notebook and REST-API access to all your processed data
Direct Notebook and REST-API access to all your processed data
Direct Notebook and REST-API access to all your processed data
Direct Notebook and REST-API access to all your processed data
Use familiar bioinformatics tools for analysis or train custom AI models
Use familiar bioinformatics tools for analysis or train custom AI models
Use familiar bioinformatics tools for analysis or train custom AI models
Use familiar bioinformatics tools for analysis or train custom AI models
Uniform processing with best-in-class pipelines
Uniform processing with best-in-class pipelines
Uniform processing with best-in-class pipelines
Uniform processing with best-in-class pipelines
More features extracted, faster turnaround, lower cost
More features extracted, faster turnaround, lower cost
More features extracted, faster turnaround, lower cost
More features extracted, faster turnaround, lower cost
100K+ curated samples and study data from publications and partners
100K+ curated samples and study data from publications and partners
100K+ curated samples and study data from publications and partners
100K+ curated samples and study data from publications and partners
Provides views and insights beyond limitations of your data - and extra statistical power for analyses
Provides views and insights beyond limitations of your data - and extra statistical power for analyses
Provides views and insights beyond limitations of your data - and extra statistical power for analyses
Provides views and insights beyond limitations of your data - and extra statistical power for analyses
Private, isolated instances
Private, isolated instances
Private, isolated instances
Private, isolated instances
Your data and analyses stay yours
Your data and analyses stay yours
Your data and analyses stay yours
Your data and analyses stay yours
Focus on Conclusions, Not Pipelines.
Focus on Conclusions, Not Pipelines.
Focus on Conclusions, Not Pipelines.
Your samples are processed using our distributed, efficient, best-in-class cloud pipelines to extract as many features as possible from your sequencing data across all forms we support.
Your samples are processed using our distributed, efficient, best-in-class cloud pipelines to extract as many features as possible from your sequencing data across all forms we support.
Your samples are processed using our distributed, efficient, best-in-class cloud pipelines to extract as many features as possible from your sequencing data across all forms we support.
For example, with RNA-seq, we perform: Quality control, contaminant detection, read trimming, mapping, expression quantification, novel transcript detection, structure variant calling, and more are all taken care of with state-of-the-art tools. The results are put into structured formats aligned with all other study data and sequencing – and are accessible to chat.
For example, with RNA-seq, we perform: Quality control, contaminant detection, read trimming, mapping, expression quantification, novel transcript detection, structure variant calling, and more are all taken care of with state-of-the-art tools. The results are put into structured formats aligned with all other study data and sequencing – and are accessible to chat.
For example, with RNA-seq, we perform: Quality control, contaminant detection, read trimming, mapping, expression quantification, novel transcript detection, structure variant calling, and more are all taken care of with state-of-the-art tools. The results are put into structured formats aligned with all other study data and sequencing – and are accessible to chat.
Run Advanced Tools, Right From the Chat.
Run Advanced Tools, Right From the Chat.
Run Advanced Tools, Right From the Chat.
Ask the chat for differential expression, differential pathway expression, or gene set enrichment (among others), and it will respond in minutes.
Ask the chat for differential expression, differential pathway expression, or gene set enrichment (among others), and it will respond in minutes.
Ask the chat for differential expression, differential pathway expression, or gene set enrichment (among others), and it will respond in minutes.
Ask the chat for differential expression, differential pathway expression, or gene set enrichment (among others), and it will respond in minutes.
Create downloadable tables and plots, such as UMAP heatmaps, or volcano plots by describing them.
Create downloadable tables and plots, such as UMAP heatmaps, or volcano plots by describing them.
Create downloadable tables and plots, such as UMAP heatmaps, or volcano plots by describing them.
Create downloadable tables and plots, such as UMAP heatmaps, or volcano plots by describing them.
Ask complex questions of your data leveraging the power of integration with the LLM
eg. “Which of my genes of interest are expressed as surface proteins…?”
Ask complex questions of your data leveraging the power of integration with the LLM
eg. “Which of my genes of interest are expressed as surface proteins…?”
Ask complex questions of your data leveraging the power of integration with the LLM
eg. “Which of my genes of interest are expressed as surface proteins…?”
Ask complex questions of your data leveraging the power of integration with the LLM
eg. “Which of my genes of interest are expressed as surface proteins…?”
Deploy Your Own Private Instance
Deploy Your Own Private Instance
Deploy Your Own Private Instance
Deploy Your Own Private Instance
Your data stays your data. Each instance of the platform is deployed separately on the cloud and accessed securely
Your data stays your data. Each instance of the platform is deployed separately on the cloud and accessed securely
Your data stays your data. Each instance of the platform is deployed separately on the cloud and accessed securely
Sucess Stories
Sucess Stories
Sucess Stories
Sucess Stories
"Ocean's platform clarified the mechanism of action and key factors influencing therapeutic response–helping guide our indication selection."
"Ocean's platform clarified the mechanism of action and key factors influencing therapeutic response–helping guide our indication selection."
"Ocean's platform clarified the mechanism of action and key factors influencing therapeutic response–helping guide our indication selection."
"Ocean's platform clarified the mechanism of action and key factors influencing therapeutic response–helping guide our indication selection."
CSO, Biotech
CSO, Biotech
CSO, Biotech
CSO, Biotech
"Ocean enabled us to integrate several large-scale patient datasets and identify novel drug targets that successfully passed preclinical validation."
"Ocean enabled us to integrate several large-scale patient datasets and identify novel drug targets that successfully passed preclinical validation."
"Ocean enabled us to integrate several large-scale patient datasets and identify novel drug targets that successfully passed preclinical validation."
"Ocean enabled us to integrate several large-scale patient datasets and identify novel drug targets that successfully passed preclinical validation."
Director, Drug Discovery, Cancer Center
Director, Drug Discovery, Cancer Center
Director, Drug Discovery, Cancer Center
Director, Drug Discovery, Cancer Center
Signature Mining in DeepSea™ for Label Expansion
Signature Mining in DeepSea™ for Label Expansion
Signature Mining in DeepSea™ for Label Expansion
Signature Mining in DeepSea™ for Label Expansion
Using DeepSea™ (100 k+ uniform transcriptomes), we screened a sponsor’s response signature across rare diseases and normal tissues, confirming prevalence in three indications and revealing two new high-potential opportunities for label expansion.
Confidential client study, 2024
Using DeepSea™ (100 k+ uniform transcriptomes), we screened a sponsor’s response signature across rare diseases and normal tissues, confirming prevalence in three indications and revealing two new high-potential opportunities for label expansion.
Confidential client study, 2024
Using DeepSea™ (100 k+ uniform transcriptomes), we screened a sponsor’s response signature across rare diseases and normal tissues, confirming prevalence in three indications and revealing two new high-potential opportunities for label expansion.
Confidential client study, 2024
Using DeepSea™ (100 k+ uniform transcriptomes), we screened a sponsor’s response signature across rare diseases and normal tissues, confirming prevalence in three indications and revealing two new high-potential opportunities for label expansion.
Confidential client study, 2024
Mechanism-Based Validation of a Melanoma Agent
Mechanism-Based Validation of a Melanoma Agent
Mechanism-Based Validation of a Melanoma Agent
Mechanism-Based Validation of a Melanoma Agent
A novel melanoma therapy showed strong phenotypic response but no molecular rationale. Deep RNA-seq analysis revealed 22 immune-modulatory pathways with favorable impact, supplying the mechanistic evidence needed for IND advancement.
Confidential client study, 2022.
A novel melanoma therapy showed strong phenotypic response but no molecular rationale. Deep RNA-seq analysis revealed 22 immune-modulatory pathways with favorable impact, supplying the mechanistic evidence needed for IND advancement.
Confidential client study, 2022.
A novel melanoma therapy showed strong phenotypic response but no molecular rationale. Deep RNA-seq analysis revealed 22 immune-modulatory pathways with favorable impact, supplying the mechanistic evidence needed for IND advancement.
Confidential client study, 2022.
A novel melanoma therapy showed strong phenotypic response but no molecular rationale. Deep RNA-seq analysis revealed 22 immune-modulatory pathways with favorable impact, supplying the mechanistic evidence needed for IND advancement.
Confidential client study, 2022.
Novel Gene Targets in ICI-Resistant Gastric Cancer
Novel Gene Targets in ICI-Resistant Gastric Cancer
Novel Gene Targets in ICI-Resistant Gastric Cancer
Novel Gene Targets in ICI-Resistant Gastric Cancer
With Samsung Medical Center (Korea), we re-analyzed tumor RNA-seq from ICI non-responders and uncovered 7 previously unreported gene targets linked to immune evasion, providing new therapeutic hypotheses for gastric cancer.
Presented in ASCO 2020 abstract.
With Samsung Medical Center (Korea), we re-analyzed tumor RNA-seq from ICI non-responders and uncovered 7 previously unreported gene targets linked to immune evasion, providing new therapeutic hypotheses for gastric cancer.
Presented in ASCO 2020 abstract.
With Samsung Medical Center (Korea), we re-analyzed tumor RNA-seq from ICI non-responders and uncovered 7 previously unreported gene targets linked to immune evasion, providing new therapeutic hypotheses for gastric cancer.
Presented in ASCO 2020 abstract.
With Samsung Medical Center (Korea), we re-analyzed tumor RNA-seq from ICI non-responders and uncovered 7 previously unreported gene targets linked to immune evasion, providing new therapeutic hypotheses for gastric cancer.
Presented in ASCO 2020 abstract.
Rescued Drug Candidate After Failed Phase 2
Rescued Drug Candidate After Failed Phase 2
Rescued Drug Candidate After Failed Phase 2
Rescued Drug Candidate After Failed Phase 2
A biopharma partner’s Phase 2 trial missed its endpoint. By re-mining PK/PD and transcriptomic data, we traced the setback to indication selection, administration parameters, and critical formulation factors. Collaboratively designed animal studies restored evidence of efficacy—leading to a successful acquisition.
Confidential client study, 2023.
A biopharma partner’s Phase 2 trial missed its endpoint. By re-mining PK/PD and transcriptomic data, we traced the setback to indication selection, administration parameters, and critical formulation factors. Collaboratively designed animal studies restored evidence of efficacy—leading to a successful acquisition.
Confidential client study, 2023.
A biopharma partner’s Phase 2 trial missed its endpoint. By re-mining PK/PD and transcriptomic data, we traced the setback to indication selection, administration parameters, and critical formulation factors. Collaboratively designed animal studies restored evidence of efficacy—leading to a successful acquisition.
Confidential client study, 2023.
A biopharma partner’s Phase 2 trial missed its endpoint. By re-mining PK/PD and transcriptomic data, we traced the setback to indication selection, administration parameters, and critical formulation factors. Collaboratively designed animal studies restored evidence of efficacy—leading to a successful acquisition.
Confidential client study, 2023.
Predictive Markers for Eribulin Response in mCRC
Predictive Markers for Eribulin Response in mCRC
Predictive Markers for Eribulin Response in mCRC